Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09SMA
|
|||
Drug Name |
PMID25666693-Compound-128
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
Company |
Sanofi-Aventis
|
|||
Structure |
Download2D MOL |
|||
Formula |
C25H20FN5O
|
|||
Canonical SMILES |
C1CC2=NC3=C(N2C1)C=CC(=C3)NC(=O)C4=CC5=C(N4CC6=CC=NC=C6)C=CC(=C5)F
|
|||
InChI |
1S/C25H20FN5O/c26-18-3-5-21-17(12-18)13-23(31(21)15-16-7-9-27-10-8-16)25(32)28-19-4-6-22-20(14-19)29-24-2-1-11-30(22)24/h3-10,12-14H,1-2,11,15H2,(H,28,32)
|
|||
InChIKey |
GBRKESHSZHLQFC-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Inflammatory mediator regulation of TRP channels | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
Reactome | TRP channels |
References | Top | |||
---|---|---|---|---|
REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.